ATE523196T1 - Mitotische kinesinhemmer und verfahren zu ihrer verwendung - Google Patents

Mitotische kinesinhemmer und verfahren zu ihrer verwendung

Info

Publication number
ATE523196T1
ATE523196T1 AT05819172T AT05819172T ATE523196T1 AT E523196 T1 ATE523196 T1 AT E523196T1 AT 05819172 T AT05819172 T AT 05819172T AT 05819172 T AT05819172 T AT 05819172T AT E523196 T1 ATE523196 T1 AT E523196T1
Authority
AT
Austria
Prior art keywords
methods
inhibitors
mitotic kinesin
kinesin inhibitors
pharmaceutical compositions
Prior art date
Application number
AT05819172T
Other languages
English (en)
Inventor
Jeremy Hans
Eli M Wallace
Qian Zhao
Joseph P Lyssikatos
Tom Aicher
Ellen Laird
John Robinson
Shelley Allen
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of ATE523196T1 publication Critical patent/ATE523196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/201—Esters of thiophosphorus acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT05819172T 2004-10-19 2005-10-18 Mitotische kinesinhemmer und verfahren zu ihrer verwendung ATE523196T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62004804P 2004-10-19 2004-10-19
US11/252,232 US7449486B2 (en) 2004-10-19 2005-10-17 Mitotic kinesin inhibitors and methods of use thereof
PCT/US2005/037305 WO2006044825A2 (en) 2004-10-19 2005-10-18 Mitotic kinesin inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE523196T1 true ATE523196T1 (de) 2011-09-15

Family

ID=36203637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819172T ATE523196T1 (de) 2004-10-19 2005-10-18 Mitotische kinesinhemmer und verfahren zu ihrer verwendung

Country Status (26)

Country Link
US (8) US7449486B2 (de)
EP (1) EP1809280B1 (de)
JP (4) JP5128283B2 (de)
KR (1) KR101280755B1 (de)
CN (4) CN102532051A (de)
AT (1) ATE523196T1 (de)
AU (1) AU2005295403B2 (de)
BR (1) BRPI0518228B8 (de)
CA (4) CA2852516C (de)
CY (1) CY1112238T1 (de)
DK (1) DK1809280T3 (de)
ES (1) ES2370774T3 (de)
HR (1) HRP20110764T1 (de)
IL (2) IL182417A0 (de)
ME (1) ME01950B (de)
MX (1) MX2007004547A (de)
NO (1) NO341725B1 (de)
NZ (1) NZ554306A (de)
PL (1) PL1809280T3 (de)
PT (1) PT1809280E (de)
RS (1) RS52037B (de)
RU (1) RU2426729C2 (de)
SI (1) SI1809280T1 (de)
TW (1) TWI357900B (de)
WO (1) WO2006044825A2 (de)
ZA (1) ZA200703168B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1847534T1 (sl) * 2001-12-11 2011-10-28 Kyowa Hakko Kirin Co Ltd Tiadiazolinski derivati za zdravljenje raka
CN1774428B (zh) * 2003-04-18 2010-06-16 协和发酵麒麟株式会社 M期驱动蛋白抑制剂
US20070276017A1 (en) * 2003-06-10 2007-11-29 Chikara Murakata Thiadiazoline Derivative
CA2576057A1 (en) * 2004-08-18 2006-03-23 Merck & Co., Inc. Mitotic kinesin inhibitors
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
US20080262049A1 (en) * 2005-03-22 2008-10-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent for Hematopoietic Tumor
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
JP2010505870A (ja) * 2006-10-03 2010-02-25 アレイ バイオファーマ、インコーポレイテッド 有糸分裂キネシン阻害剤としてのオキサジアゾール誘導体およびチアジアゾール誘導体、ならびにそれらの使用方法
WO2008070739A1 (en) * 2006-12-06 2008-06-12 Cytokinetics, Inc. Ksp activators
US8796460B2 (en) * 2007-10-19 2014-08-05 Mercky Sharp & Dohme Corp. Compounds for inhibiting KSP kinesin activity
WO2009061596A1 (en) * 2007-11-09 2009-05-14 Schering Corporation Compounds for inhibiting ksp kinesin activity
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
EP2349259B1 (de) * 2008-10-16 2015-12-23 Array Biopharma, Inc. Mitose-hemmer zur verstärkung der apoptose in der therapie
US20120070370A1 (en) * 2009-05-13 2012-03-22 Siddiqui M Arshad Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
AU2011224287B2 (en) * 2010-03-12 2015-03-26 Omeros Corporation PDE10 inhibitors and related compositions and methods
FR2991199B1 (fr) * 2012-05-30 2015-05-15 IFP Energies Nouvelles Procede de preparation d'un catalyseur mettant en oeuvre une etape de sechage rapide et son utilisation pour la synthese fischer-tropsch
EP2882436A1 (de) 2012-08-13 2015-06-17 Array Biopharma, Inc. Arry-520 zur verwendung bei der behandlung von krebs bei patienten mit niedrigem aag
EP3030236A1 (de) 2013-08-08 2016-06-15 Array Biopharma, Inc. Filanesib, kombiniert mit pomalidomid für verbesserte antitumorwirkung
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) * 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2016207104A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
HK1246717A1 (zh) 2015-06-23 2018-09-14 Bayer Pharma Aktiengesellschaft Ksp抑制剂的靶向缀合物
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
CA3103327A1 (en) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025096684A1 (en) * 2023-10-30 2025-05-08 University Of Health Sciences And Pharmacy In St. Louis Err modulators
WO2025096683A1 (en) * 2023-10-30 2025-05-08 University Of Health Sciences And Pharmacy In St. Louis Err modulators
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2702803A (en) 1954-04-12 1955-02-22 Lilly Co Eli Substituted heterodiazoles
SU1065410A1 (ru) * 1982-05-07 1984-01-07 Днепропетровский Ордена Трудового Красного Знамени Химико-Технологический Институт Им.Ф.Э.Дзержинского Способ получени 2-амино-5-трет-алкил-1,3,4-тиадиазолов
EP0217519B1 (de) 1985-08-31 1992-02-05 FISONS plc 5-gliedrige heterocyclische Angiotensin-Umwandlungsenzym-Inhibitoren
US4762072A (en) * 1986-10-07 1988-08-09 Westinghouse Electric Corp. Desk and space dividing wall panel assembly
GB8625774D0 (en) 1986-10-28 1986-12-03 Reckitt & Colmann Prod Ltd Thiadiazole derivative
JPH0572686A (ja) 1991-09-11 1993-03-26 Konica Corp ハロゲン化銀写真感光材料
AU4288293A (en) 1992-04-27 1993-11-29 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
JPH10513443A (ja) 1995-02-02 1998-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ＨＴ▲下２ｃ▼レセプターアンタゴニスト活性を有する複素環化合物
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
HRP980093A2 (en) 1997-02-28 1998-12-31 Lilly Co Eli Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds
JP2002508361A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用
US6235762B1 (en) 1998-11-23 2001-05-22 American Cyanamid Company 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents
JP2000159756A (ja) 1998-11-23 2000-06-13 American Cyanamid Co ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤
AU2482700A (en) * 1999-01-13 2000-08-01 Warner-Lambert Company 1-heterocycle substituted diarylamines
US6380187B2 (en) 1999-03-25 2002-04-30 Dingwei Tim Yu Class of thiomorpholino substituted thiazoles
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001234741A1 (en) 2000-02-04 2001-08-14 Biogen, Inc. Integrin antagonists
EP1419770A4 (de) 2001-08-24 2005-08-03 Shionogi & Co Mittel zur beschleunigung der expression von apo ai
SI1847534T1 (sl) 2001-12-11 2011-10-28 Kyowa Hakko Kirin Co Ltd Tiadiazolinski derivati za zdravljenje raka
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004002029A1 (de) 2002-06-25 2003-12-31 Andreas Gall Anordnung zur erfassung der nutzung von rds-rundfunkempfängern
US7294643B2 (en) * 2002-11-22 2007-11-13 Board Of Regents, The University Of Texas System UK-1 analogues: methods of preparation and use
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
CN1774428B (zh) * 2003-04-18 2010-06-16 协和发酵麒麟株式会社 M期驱动蛋白抑制剂
EP1620412A2 (de) 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclische verbindungen und deren hydroisomere
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
EP1628666B1 (de) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Verbindungen und ihre verwendungen zur modulierung von amyloid beta
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US20070276017A1 (en) * 2003-06-10 2007-11-29 Chikara Murakata Thiadiazoline Derivative
JPWO2004111023A1 (ja) 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
EP1671957A4 (de) * 2003-10-10 2007-03-14 Thiadiazolinderivate
JP2005232016A (ja) 2004-02-17 2005-09-02 Kyowa Hakko Kogyo Co Ltd オキサジアゾリン誘導体
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
CA2576057A1 (en) * 2004-08-18 2006-03-23 Merck & Co., Inc. Mitotic kinesin inhibitors
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
FR2876586B1 (fr) 2004-10-20 2007-10-12 Persee Medica Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
US20080262049A1 (en) * 2005-03-22 2008-10-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent for Hematopoietic Tumor
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
JP2010505870A (ja) 2006-10-03 2010-02-25 アレイ バイオファーマ、インコーポレイテッド 有糸分裂キネシン阻害剤としてのオキサジアゾール誘導体およびチアジアゾール誘導体、ならびにそれらの使用方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
EP2882436A1 (de) 2012-08-13 2015-06-17 Array Biopharma, Inc. Arry-520 zur verwendung bei der behandlung von krebs bei patienten mit niedrigem aag
EP3030236A1 (de) 2013-08-08 2016-06-15 Array Biopharma, Inc. Filanesib, kombiniert mit pomalidomid für verbesserte antitumorwirkung

Also Published As

Publication number Publication date
CA2952920A1 (en) 2006-04-27
US20120270803A1 (en) 2012-10-25
CA2852516A1 (en) 2006-04-27
CN103626720B (zh) 2016-11-16
US8623895B2 (en) 2014-01-07
ES2370774T3 (es) 2011-12-22
DK1809280T3 (da) 2011-10-31
WO2006044825A2 (en) 2006-04-27
TWI357900B (en) 2012-02-11
JP2015129191A (ja) 2015-07-16
RS52037B (sr) 2012-04-30
SI1809280T1 (sl) 2011-11-30
MX2007004547A (es) 2007-06-07
ME01950B (me) 2012-04-30
US7449486B2 (en) 2008-11-11
CY1112238T1 (el) 2015-12-09
AU2005295403B2 (en) 2011-05-19
US9102639B2 (en) 2015-08-11
JP2014139249A (ja) 2014-07-31
BRPI0518228B1 (pt) 2020-10-20
PL1809280T3 (pl) 2011-12-30
CN103951633B (zh) 2017-05-10
JP5757666B2 (ja) 2015-07-29
CN101083988A (zh) 2007-12-05
JP2012233012A (ja) 2012-11-29
EP1809280B1 (de) 2011-09-07
RU2007118632A (ru) 2008-11-27
ZA200703168B (en) 2008-06-25
WO2006044825A3 (en) 2006-10-05
US20150210658A1 (en) 2015-07-30
PT1809280E (pt) 2011-11-15
US20180334441A1 (en) 2018-11-22
EP1809280A2 (de) 2007-07-25
US9499503B2 (en) 2016-11-22
NO20072558L (no) 2007-07-18
US20080182992A1 (en) 2008-07-31
CA2584866A1 (en) 2006-04-27
CA2868912A1 (en) 2006-04-27
CA2584866C (en) 2014-09-23
CN103626720A (zh) 2014-03-12
US8236825B2 (en) 2012-08-07
US20060100161A1 (en) 2006-05-11
KR101280755B1 (ko) 2013-07-08
US10017482B2 (en) 2018-07-10
US20110201651A1 (en) 2011-08-18
CN103951633A (zh) 2014-07-30
TW200621736A (en) 2006-07-01
JP5128283B2 (ja) 2013-01-23
NZ554306A (en) 2010-12-24
JP5911909B2 (ja) 2016-04-27
NO341725B1 (no) 2018-01-08
HK1106131A1 (en) 2008-03-07
EP1809280A4 (de) 2009-10-21
CA2852516C (en) 2015-06-02
BRPI0518228A (pt) 2008-11-04
IL219857A0 (en) 2012-06-28
AU2005295403A1 (en) 2006-04-27
BRPI0518228B8 (pt) 2021-05-25
IL182417A0 (en) 2007-07-24
US20140094603A1 (en) 2014-04-03
CA2868912C (en) 2017-01-03
CN102532051A (zh) 2012-07-04
US7956073B2 (en) 2011-06-07
RU2426729C2 (ru) 2011-08-20
KR20070084348A (ko) 2007-08-24
HRP20110764T1 (hr) 2011-12-31
JP2008516982A (ja) 2008-05-22
US20170066733A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
TW200510416A (en) P38 inhibitors and methods of use thereof
IL186707A (en) Mitotic quinine inhibitors and medical preparations containing them
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE537826T1 (de) Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
ATE458485T1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
MY142329A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE450256T1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
WO2008042928A3 (en) Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
TW200716561A (en) P38 inhibitors and methods of use thereof
UA98926C2 (ru) Ингибитор митотических кинезинов и его использование
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809280

Country of ref document: EP